APP下载

蛹虫草治疗慢性肾脏病的临床应用

2020-12-23孙婷丽

中国实用医药 2020年32期
关键词:慢性肾脏病

孙婷丽

【摘要】 目的 分析蛹蟲草在治疗慢性肾脏病(CKD)方面的分子机制。方法 98例CKD患者, 将所有患者随机分为蛹虫草组(服用蛹虫草100 mg/d, 为期3个月)和对照组(每日服用等量淀粉作安慰剂, 为期3个月), 每组49例。比较两组患者治疗前后肾功能指标[尿蛋白、尿素氮(BUN)、肌酐(Cr)]、血脂指标[血清总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]、氧化还原特征指标[血清胱抑素C(Cys-C)、髓过氧化物酶(MPO)、丙二醛(MDA)、一氧化氮(NO)、超氧化物歧化酶(SOD)]水平。结果 治疗3个月后, 蛹虫草组尿蛋白、BUN、Cr水平分别为(1.36±0.45)g/24 h、(8.84±2.36)mmol/L、(149.1±25.5)μmol/L, 均低于对照组的(2.65±0.73)g/24 h、(9.72±2.38)mmol/L、(204.0±31.8)μmol/L, 差异均具有统计学意义(P<0.05)。治疗3个月后, 蛹虫草组TC、TG、LDL-C分别为(4.9±0.5)、(2.0±0.6)、(1.7±0.5)mmol/L, 均低于对照组的(5.9±0.7)、(2.4±0.9)、(2.2±0.6)mmol/L, HDL-C水平(1.9±0.5)mmol/L高于对照组的(1.7±0.5)mmol/L, 差异均具有统计学意义(P<0.05)。蛹虫草组Cys-C、MPO、MDA水平分别为(0.8±0.2)mg/L、(14.5±3.4)mg/L、(5.4±1.9)mmol/L, 均低于对照组的(1.0±0.3)mg/L、(23.3±4.3)mg/L、(8.1±2.5)mmol/L, NO(6.8±2.5)μmol/L、SOD(698.4±145.6)U/L均高于对照组的(5.8±2.1)μmol/L、(521.4±123.8)U/L, 差异均具有统计学意义(P<0.05)。结论 蛹虫草可通过影响脂质和氧化还原信号传导途径对CKD起保护作用, 为目前评估虫草素对抑制CKD的临床试验提供了进一步的支持。

【关键词】 蛹虫草;慢性肾脏病;氧化还原

DOI:10.14163/j.cnki.11-5547/r.2020.32.002

【Abstract】 Objective   To analyze the molecular mechanism of Cordyceps militaris in the treatment of chronic kidney disease (CKD). Methods   A total of 98 CKD patients were randomly divided into Cordyceps militaris group (taking Cordyceps militaris 100 mg/d for 3 months) and control group (taking the same amount of starch as a placebo daily for 3 months), with 49 cases in each group. The renal function [urinary protein, blood urea nitrogen (BUN), creatinine (Cr)], blood lipids [serum total cholesterol (TC), triglycerides (TG), low density lipoprotein cholesterol (LDL- C), high-density lipoprotein cholesterol (HDL-C)], redox characteristics [serum cystatin C (Cys-C), myeloperoxidase (MPO), malondialdehyde (MDA), nitric oxide (NO), superoxide dismutase (SOD)] levels before and after treatment were compared between the two groups. Results   3 months after treatment, the urine protein, BUN, Cr levels of Cordyceps militaris group were (1.36±0.45) g/24 h, (8.84±2.36) mmol/L and (149.1±25.5) μmol/L, which were all lower than (2.65±0.73) g/24 h, (9.72±2.38) mmol/L and (204.0±31.8) μmol/L of the control group, and the difference was statistically significant (P<0.05). 3 months after treatment, TC, TG and LDL-C of Cordyceps militaris group were (4.9±0.5), (2.0±0.6) and (1.7±0.5) mmol/L, which were all lower than (5.9±0.7), (2.4±0.9) and (2.2±0.6) mmol/L of the control group, and HDL-C (1.9±0.5) mmol/L was higher than (1.7±0.5) mmol/L of the control group, and the difference was statistically significant (P<0.05). Cys-C (0.8±0.2) mg/L, MPO (14.5±3.4) mg/L and MDA (5.4±1.9) mmol/L of Cordyceps militaris group were lower than (1.0±0.3) mg/L, (23.3±4.3) mg/L and (8.1±2.5) mmol/L of the control group, and NO (6.8±2.5) μmol/L and SOD (698.4±145.6) U/L were higher than (5.8±2.1) μmol/L and (521.4±123.8) U/L of the control group, and the difference was statistically significant (P<0.05). Conclusion   Cordyceps militaris can protect CKD by affecting lipid and redox signal transduction pathway. It provides further support for the evaluation of cordycepin to inhibit CKD clinical trials.

【Key words】 Cordyceps militaris; Chronic kidney disease; Redox

CKD通常由感染、毒素和自身免疫性疾病引起, 对公共健康构成重大威胁[1]。CKD累及肾小球、肾小管以及肾小球和小管周围的间质组织。CKD常因高水平炎症细胞破坏肾小球结构而导致肾小球损伤, 结果会阻止血液流动, 导致排尿量减少和尿毒毒素的积累。随后, 受损的肾小球会释放出红细胞, 从而发生血尿。目前, 治疗CKD的方法有很多种, 包括降糖、降压、控制尿蛋白, 但治疗费用高、副作用明显、耗时持久、且疗效欠佳。此外, CKD的治疗还受到一些禁忌证的限制, 因此, 探索新的副作用较小的抗CKD药物势在必行。蛹虫草及其特有成分虫草素具有保健作用(包括抗炎、抗癌、抗糖尿病和抗肥胖)因而受到广泛关注[2]。据报道, 虫草素具抗糖尿病和调节肾上腺的功能, 然而, 对CKD保护作用的确切分子机制尚不明确。CysC、MPO、MDA、NO、SOD参与氧化还原系统并影响肾脏疾病, 脂质和氧化还原活性在CKD治疗中起重要作用, 因此, 本研究检测相关生物标记物和化学指标, 以此探讨蛹虫草在治疗CKD方面的作用。……

登录APP查看全文

猜你喜欢

慢性肾脏病
从“毒损肾络”学说探讨慢性肾脏病诊疗的研究进展
慢性肾脏病胰岛素抵抗的发病机制、治疗策略及中药的干预作用
探讨替米沙坦联合氨氯地平治疗慢性肾脏病合并早期高血压患者的临床效果
童安荣主任医师辨证治疗慢性肾脏病经验
前列地尔治疗高龄糖尿病并慢性肾脏病患者疗效和安全性分析
羟苯磺酸钙联合复方肾衰汤治疗慢性肾脏病的护理体会
慢性肾脏病合并高血压患者食盐的摄入与降压药的关系
杞县地区慢性肾脏病发病率及病因流行病学调查
冠状动脉钙化积分与慢性肾脏病的相关性分析
复方α—酮酸用于改善乙型肝炎合并慢性肾脏病患者营养状态及肾脏功能疗效研究